Search research articles
Contact Us
Filters
Showing results (111-120 of 128) with videos related to
Page
of 13
Sort By:
Nature Communications
|
November 23, 2018
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma
Elizabeth C Randall, Kristina B Emdal, Janice K Laramy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma
Rachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 30, 2024
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma
Veronica Rendo, Eudocia Q Lee, Connor Bossi, et al.
Nature Metabolism
|
April 29, 2026
Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice
Milan R Savani, Bingbing Li, Bailey C Smith, et al.
Neuro-Oncology
|
May 29, 2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma
Bianca-Maria Marin, Kendra A Porath, Sonia Jain, et al.
Biorxiv : the Preprint Server for Biology
|
August 8, 2025
Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice
Milan R Savani, Bailey C Smith, Wen Gu, et al.
The Lancet. Oncology
|
October 15, 2022
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial
Eleonora F Spinazzi, Michael G Argenziano, Pavan S Upadhyayula, et al.
Nature
|
September 3, 2025
Rewiring of cortical glucose metabolism fuels human brain cancer growth
Andrew J Scott, Anjali Mittal, Baharan Meghdadi, et al.
Science Translational Medicine
|
February 19, 2025
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
Veronica Rendo, Eudocia Q Lee, Connor Bossi, et al.
Science Translational Medicine
|
October 8, 2025
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
Alexander L Ling, Jennifer Gantchev, Michael C Prabhu, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 128) with videos related to
Sort By:
Page
of 13
Nature Communications
|
November 23, 2018
Integrated mapping of pharmacokinetics and pharmacodynamics in a patient-derived xenograft model of glioblastoma
Elizabeth C Randall, Kristina B Emdal, Janice K Laramy, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 1, 2025
Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH-Wild-type Glioblastoma
Rachael A Vaubel, Wenjuan Zhang, Ju-Hee Oh, et al.
Medrxiv : the Preprint Server for Health Sciences
|
August 30, 2024
Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma
Veronica Rendo, Eudocia Q Lee, Connor Bossi, et al.
Nature Metabolism
|
April 29, 2026
Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice
Milan R Savani, Bingbing Li, Bailey C Smith, et al.
Neuro-Oncology
|
May 29, 2021
Heterogeneous delivery across the blood-brain barrier limits the efficacy of an EGFR-targeting antibody drug conjugate in glioblastoma
Bianca-Maria Marin, Kendra A Porath, Sonia Jain, et al.
Biorxiv : the Preprint Server for Biology
|
August 8, 2025
Nitrogen metabolism profiling reveals cell state-specific pyrimidine synthesis pathway choice
Milan R Savani, Bailey C Smith, Wen Gu, et al.
The Lancet. Oncology
|
October 15, 2022
Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial
Eleonora F Spinazzi, Michael G Argenziano, Pavan S Upadhyayula, et al.
Nature
|
September 3, 2025
Rewiring of cortical glucose metabolism fuels human brain cancer growth
Andrew J Scott, Anjali Mittal, Baharan Meghdadi, et al.
Science Translational Medicine
|
February 19, 2025
A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma
Veronica Rendo, Eudocia Q Lee, Connor Bossi, et al.
Science Translational Medicine
|
October 8, 2025
Serial multiomics uncovers anti-glioblastoma responses not evident by routine clinical analyses
Alexander L Ling, Jennifer Gantchev, Michael C Prabhu, et al.
Page
of 13